ITIain Gregory Thomson

Iain Gregory Thomson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Iain Gregory Thomson has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cost–Utility Analysis of Wireless Versus Catheter‐Based Oesophageal pH Monitoring in the Pre‐Operative Assessment of Anti‐Reflux Surgery: A Decision‐Analytic Model

    by Du H. Phan, Naomi Moy, Iain G. Thomson, Adam J. Frankel

    Background: Distal oesophageal pH testing is an important component of the pre‐operative workup for anti‐reflux surgery, providing diagnostic confirmation and prognostic information. Catheter‐based reflux testing is currently the standard modality in Australia. Although associated with improved patient tolerability, wireless testing remains limited by access and funding restrictions. Methods: A cost–utility analysis was conducted to compare the cost‐effectiveness of wireless versus catheter‐based reflux monitoring before anti‐reflux surgery. Health service costs (administrative, labour, and equipment) and EuroQol 5‐Dimension‐derived utility weights were used to calculate incremental costs per quality‐adjusted life‐year (QALY) over a one‐year time horizon. Results: Wireless pH monitoring was associated with marginally lower costs and higher QALYs compared with catheter‐based monitoring (AUD $11001.51 vs. AUD $11210.47; 0.87 vs. 0.82 QALYs). The base‐case incremental cost‐effectiveness ratio was −AUD $5026.64 per QALY, indicating that wireless monitoring was the dominant strategy. At a willingness‐to‐pay threshold of AUD $50 000 per QALY, the incremental net monetary benefit was AUD $2287.47, indicating potential cost‐effectiveness. One‐way sensitivity analyses suggested that base‐case findings were robust across key parameter variations. Conclusion: Within this model evaluating the pH testing component of the pre‐operative work‐up, wireless monitoring may represent a cost‐effective alternative to catheter‐based monitoring without substantially increasing healthcare costs.

  • Beyond symptom improvement: a qualitative study of patient-defined treatment goals and surgical success after anti-reflux surgery

    by Du Huynh Phan, Nicole Marinucci, Iain Gregory Thomson, Adam John Frankel

    Summary: Gastro-esophageal reflux disease (GORD) has multifactorial effects that substantially impair quality of life. Anti-reflux surgery (ARS) is an established treatment for appropriately selected patients; however, current outcome reporting is largely symptom-focused and may not fully capture patient-derived goals and expectations that shape perceptions of surgical success. A qualitative study using semi-structured interviews and inductive thematic analysis was conducted in postoperative patients at a tertiary upper gastrointestinal surgical unit in Australia. Patient-identified experiences of GORD, expectations of surgery, and perceived determinants of surgical success were explored. Participants described GORD as a chronic condition with pervasive impacts on daily functioning and psychosocial wellbeing. Surgery was primarily motivated by the desire to restore everyday functioning, reduce medication reliance, and exclude serious pathology. Surgical success was evaluated according to multidimensional, patient-defined goals centered on functional improvement. Satisfaction depended on concordance between post-operative outcomes and preoperative expectations. Rather than pursuing complete symptom resolution, some patients may accept trade-offs to prioritize individual treatment goals. Dissatisfaction was commonly associated with new non-reflux symptoms, particularly when these caused unexpected functional limitations, despite effective reflux control. Patients evaluated satisfaction according to the extent to which postoperative outcomes aligned with patient-specific, function-focused treatment goals. A patient-centered approach to ARS should therefore include exploration of patients’ motivations for surgery and goals to guide expectation setting and shared decision-making. Incorporating functional outcomes alongside conventional symptom measures may further improve the evaluation of surgical success.

  • Textbook outcomes for oesophagectomy: A valid composite measure assessment tool for surgical performance in a specialist unit

    by Michael Yulong Wu, Richard J. McGregor, Justin Scott, B Mark Smithers, Janine Thomas, Adam Frankel, Andrew Barbour, Iain Thomson


  • Open Access

    Laparoscopic fundoplication versus laparoscopic Roux-en-Y gastric bypass for gastro-oesophageal reflux disease in obese patients: protocol for a randomized clinical trial

    by Adam Frankel, Iain Thomson, Ayesha Shah, Chen Chen, Syeda Farah Zahir, Andrew Barbour, Gerald Holtmann, B Mark Smithers

    Laparoscopic fundoplication (LF) is the standard surgical procedure for the treatment of gastro-oesophageal reflux disease (GORD). Laparoscopic Roux-en-Y gastric bypass (LRYGB) is commonly performed to achieve weight loss in obese patients, but it also has anti-reflux properties. Hence, in the obese population suffering from GORD, LRYGB could be an alternative to LF. The aim of this trial will be to compare LF and LRYGB in an obese population presenting with GORD and being considered for surgery. This will be an investigator-initiated randomized clinical trial. The research population will be obese patients (BMI 30–34.9 with waist circumference more than 88 cm (women) or more than 102 cm (men), or BMI 35–40 with any waist circumference) referred to a public hospital for consideration of anti-reflux surgery. The primary aim of the study will be to determine the efficacy of LF compared with LRYGB on subjective and objective control of GORD. Secondary aims include determining early and late surgical morbidity and the side-effect profile of LF compared with LRYGB and to quantify any non-reflux benefits of LRYGB (including overall quality of life) compared with LF. This trial will determine whether LRYGB is effective and acceptable as an alternative to LF for the surgical treatment of GORD in obese patients Registration number: Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12622000636752p (https://www.anzctr.org.au/).


  • Open Access

    Complications and survival after hybrid and fully minimally invasive oesophagectomy

    by M M K Veenstra, B M Smithers, E Visser, D Edholm, S Brosda, J M Thomas, D C Gotley, I G Thomson, B P L Wijnhoven, A P Barbour

    Minimally invasive oesophagectomy (MIO) is reported to produce fewer respiratory complications than open oesophagectomy. This study assessed differences in postoperative complications between MIO and hybrid MIO (HMIO) employing thoracoscopy and laparotomy, along with the influence of co-morbidities on postoperative outcomes. Patients with oesophageal cancer undergoing three-stage MIO or three-stage HMIO between 1999 and 2018 were identified from a prospectively developed database, which included patient demographics, co-morbidities, preoperative therapies, and cancer stage. The primary outcome was postoperative complications in the two groups. Secondary outcomes included duration of operation, blood transfusion requirement, duration of hospital stay, and overall survival. There were 828 patients, of whom 722 had HMIO and 106 MIO, without significant baseline differences. Median duration of operation was longer for MIO (325 versus 289 min; P < 0.001), but with less blood loss (median 250 versus 300 ml; P < 0.001) and a shorter hospital stay (median 12 versus 13 days; P = 0.006). Respiratory complications were not associated with operative approach (31.1 versus 35.2 per cent for MIO and HMIO respectively; P = 0.426). Anastomotic leak rates (10.4 versus 10.2 per cent) and 90-day mortality (1.0 versus 1.7 per cent) did not differ. Cardiac co-morbidity was associated with more medical and surgical complications. Overall survival was associated with AJCC stage and co-morbidities, but not operative approach. MIO had a small benefit in terms of blood loss and hospital stay, but not in operating time. Oncological outcomes were similar in the two groups. Postoperative complications were associated with pre-existing cardiorespiratory co-morbidities rather than operative approach.


  • Neoadjuvant therapy reduces cardiopulmunary function in patients undegoing oesophagectomy

    by Iain G. Thomson, Matthew P. Wallen, Adrian Hall, Rebekah Ferris, David C. Gotley, Andrew P. Barbour, Andrew Lee, Janine Thomas, Bernard M. Smithers

    Neoadjuvant therapy (NAT) for oesophageal cancer may reduce cardiopulmonary function, assessed by cardiopulmonary exercise testing (CPEX). Impaired cardiopulmonary function is associated with mortality following esophagectomy. We sought to assess the impact of NAT on cardiopulmonary function using CPEX and assessing the clinical relevance of any change in particular if changes were associated with post-operative morbidity. This was a prospective, cohort study of 40 patients in whom CPEX was performed before and after NAT. Thirty-eight patients underwent surgery and follow-up with perioperative outcomes measured. The primary variables derived from CPEX were the anaerobic threshold (AT) and peak oxygen uptake (V˙O2peak). There were significant reductions in the AT (pre-NAT: 12.4 ± 3.0 vs. post-NAT 10.6 ± 2.0 mL kg-1.min-1; p = 0.001). This reduction was also evident for V˙O2peak (pre-NAT: 16.6 ± 3.6 vs. post-NAT 14.9 ± 3.7 mL kg-1.min-1; p = 0.004). The relative reduction in V˙O2peak was greater in chemotherapy patients who developed any peri-operative morbidity (p = 0.04). For patients who underwent chemoradiotherapy, there was a significantly greater relative reduction in AT (p = 0.03) for those who encountered a respiratory complication. Cardiopulmonary function significantly declined as a result of NAT prior to oesophagectomy. The reduction in AT and V˙O2peak was similar in both the chemotherapy and chemoradiotherapy groups.


  • Long-term Health-related Quality of Life Following Esophagectomy

    by Andrew P. Barbour, Orla M. Mc Cormack, Peter J. Baker, Jodi Hirst, Lutz Krause, Sandra Brosda, Janine M. Thomas, Jane M. Blazeby, Iain G. Thomson, David C. Gotley, et al.

    The aim of this study was to assess long-term health-related quality of life (HRQL) in patients after thoracoscopic and open esophagectomy. Trials comparing minimally invasive with open transthoracic esophagectomy have shown improved short-term outcomes; however, long-term HRQL data are lacking. This prospective nonrandomized study compared HRQL and survival after thoracoscopically assisted McKeown esophagectomy (TAMK) and open transthoracic Ivor Lewis esophagectomy (TTIL) for esophageal or gastroesophageal junction (GEJ) cancer. Patients with esophageal or GEJ cancer selected for TAMK or TTIL completed baseline and follow-up HRQL assessments for up to 24 months using the EORTC generic and disease-specific measures, QLQ-C30 and QLQ-OES18. Baseline clinical variables were examined between the treatment groups and changes in mean HRQL scores over time estimated and tested using generalised estimating equations with propensity score (generated by boosted regression) adjustment. Of the 487 patients, 377 underwent TAMK and 110 underwent TTIL. Most clinical variables were similar in the 2 groups; however, there were significantly more patients with AJCC stage 3 disease who underwent TTIL than TAMK (54% vs 32%, P Results: Mean symptom scores for pain were significantly higher in the TTIL group than in TAMK for 2 years postoperatively (P = 0.036). In addition, mean constipation scores were significantly higher for the TTIL group, with a 15-point difference in mean score at 3 months postoperatively (P = 0.037). This large comprehensive nonrandomized analysis of longitudinal HRQL shows that TTIL is associated with more pain and constipation than TAMK.


  • Treatment results of curative gastric resection from a specialist Australian unit: low volume with satisfactory outcomes

    by Iain G. Thomson, David C. Gotley, Andrew P. Barbour, Ian Martin, Neil Jayasuria, Janine Thomas, Bernard M. Smithers

    The incidence of gastric cancer is decreasing in Australia, yet it remains a common cause of cancer-related mortality. Surgical resection remains the cornerstone of curative treatment. High-volume specialized units have reported superior perioperative and oncological outcomes. The role of D2 lymphadenectomy has been controversial as a result of concerns over increased morbidity. Our aim is to report the perioperative and oncological outcomes of curative gastric resection from a specialist Australian upper GI unit. Data from a prospectively maintained database were reviewed for all patients undergoing curative resection for gastric adenocarcinoma from a single unit during a 12-year period. Perioperative and long-term outcomes were compiled. There were 255 curative gastric resections during 12 years. An R0 resection was performed in 96 % with a perioperative mortality rate of 1.6 %. A D2 dissection was performed in 85 % of cases in the past 6 years, with no increase in perioperative morbidity or mortality detected. The 5-year overall survival was 53 %. Our results demonstrate that both short- and long-term outcomes of surgical resection in gastric cancer patients, comparable to international high-volume centers, can be achieved in an Australian upper GI unit. A D2 lymph node dissection can be performed safely without any increase in perioperative risk in a specialist unit that has the necessary training but also the perioperative support structures to manage these complex patients.